產品詳情
簡單介紹：
Anti-OVCA1抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-OVCA1抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-OVCA1
Cat. Number:
Anti-OVCA1抗體KL-5714R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
OVCA1 is required for the first step in the synthesis of diphthamide, a unique posttranslationally modified histidine found only in translation elongation factor-2 (EEF2; MIM 130610). This modification is conserved fromAnti-OVCA1抗體 archaebacteria to humans and serves as the target for ADP-ribosylation and inactivation of EEF2 by diphtheria toxin (DT) and Pseudomonas exotoxin A. OVCA1 is one of several enzymes involved in synthesis of diphthamide in EEF2.
Also known as:
Candidate tumor suppressor in ovarian cancer 1; Diphthamide biosynthesis protein 1; Diphthamide biosynthesis protein 2 homolog like 1; Diphthamide biosynthesis protein 2 like; Diptheria toxin resistance protein required for Anti-OVCA1抗體diphthamide biosynthesis (Saccharomyces) like 1 ; Diptheria toxin resistance protein required for diphthamide biosynthesis like 1; DPH like 1 (S. cerevisiae); DPH like 1; DPH1; DPH1 homolog (S. cerevisiae); DPH1 homolog; DPH2 like 1; DPH2L; DPH2L1; HsDph1; Ovarian cancer associated gene 1; Ovarian cancer associated gene 1 protein; Ovarian tumor suppressor candidate 1; DPH1_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity Anti-OVCA1抗體purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human OVCA1.
●
Predicted Molecular Weight: 49kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-OVCA1抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-OVCA1抗體
Optimal working dilutions must be determined by the end user.
